Edap TMSFOCL +1.91%53 EBIT per Share is $-1.10 as of Mar. 2026. GuruFocus rates FOCL with a GF Score™ of 53/100 and a GF Value™ of $4.52 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 107 Medical Distribution companies, Edap TMS ranks worse than 97.2% on this metric.
Edap TMS's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.20.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.10.
During the past 3 years, the average EBIT per Share Growth Rate was -70.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Edap TMS's EBIT per Share or its related term are showing as below:
FOCL'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -120 Med: 14.55 Max: 81
Current: -70.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Edap TMS was 81.00% per year. The lowest was -120.00% per year. And the median was 14.55% per year.
FOCL's 3-Year EBIT Growth Rate is ranked worse than 97.2% of 107
companies
in the Medical Distribution industry
Industry Median: 4.2
vs FOCL: -70.60
Edap TMS's EBIT for the
three
months ended in Mar. 2026 was $-7.4 Mil.
Edap TMS (NAS:FOCL) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Edap TMS EBIT per Share Related Terms
Edap TMS EBIT per Share Historical Data
* Premium members only.
The historical data trend for Edap TMS's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edap TMS (FOCL) has a EBIT per Share of $-1.10 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Edap TMS and its competitors. According to the industry distribution chart, Edap TMS ranks #104 out of 107 companies in the Medical Distribution industry, placing it in the top 97.2%.
Is Edap TMS's EBIT per Share too high?
Edap TMS's current EBIT per Share is $-1.10. Based on the distribution chart, Edap TMS ranks #104 out of 107 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Edap TMS has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Edap TMS's EBIT per Share compare to ACH and YI?
According to the Medical Distribution industry distribution chart, Edap TMS ranks #104 out of 107 companies for EBIT per Share. This places Edap TMS in the lower half of its industry. The industry median EBIT per Share is 4.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 4.20, based on 107 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Edap TMS and its competitors. For the Medical Distribution industry, the median EBIT per Share is 4.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edap TMS's current EBIT per Share is $-1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edap TMS stock overvalued right now?
Based on GuruFocus' analysis, Edap TMS (FOCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.52, compared to a current price of $5.08 — trading 12.3% above its estimated fair value. The current EBIT per Share is $-1.10. Edap TMS's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Edap TMS (FOCL), the current EBIT per Share is $-1.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edap TMS (FOCL) Overvalued in 2026?
Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued.
The current stock price of $5.08 is trading 12.3% above its estimated GF Value™ of $4.52.
GuruFocus considers Edap TMS to be Modestly Overvalued.
Key valuation signals for FOCL:
EBIT per Share: $-1.10
GF Value™: $4.52 vs. price of $5.08 (12.3% above fair value)
No single metric tells the full story. See the FOCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
53GF Score
Get the complete analysis for FOCL
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FOCL has been successfully added to your 
